Nanotechnology-enhanced immunotherapy for metastatic cancer

dc.citation.articleNumber100174en_US
dc.citation.issueNumber4en_US
dc.citation.journalTitleThe Innovationen_US
dc.citation.volumeNumber2en_US
dc.contributor.authorZhang, Peisenen_US
dc.contributor.authorMeng, Junlien_US
dc.contributor.authorLi, Yingyingen_US
dc.contributor.authorYang, Chenen_US
dc.contributor.authorHou, Yien_US
dc.contributor.authorTang, Wenen_US
dc.contributor.authorMcHugh, Kevin J.en_US
dc.contributor.authorJing, Lihongen_US
dc.date.accessioned2021-12-02T15:09:17Zen_US
dc.date.available2021-12-02T15:09:17Zen_US
dc.date.issued2021en_US
dc.description.abstractA vast majority of cancer deaths occur as a result of metastasis. Unfortunately, effective treatments for metastases are currently lacking due to the difficulty of selectively targeting these small, delocalized tumors distributed across a variety of organs. However, nanotechnology holds tremendous promise for improving immunotherapeutic outcomes in patients with metastatic cancer. In contrast to conventional cancer immunotherapies, rationally designed nanomaterials can trigger specific tumoricidal effects, thereby improving immune cell access to major sites of metastasis such as bone, lungs, and lymph nodes, optimizing antigen presentation, and inducing a persistent immune response. This paper reviews the cutting-edge trends in nano-immunoengineering for metastatic cancers with an emphasis on different nano-immunotherapeutic strategies. Specifically, it discusses directly reversing the immunological status of the primary tumor, harnessing the potential of peripheral immune cells, preventing the formation of a pre-metastatic niche, and inhibiting the tumor recurrence through postoperative immunotherapy. Finally, we describe the challenges facing the integration of nanoscale immunomodulators and provide a forward-looking perspective on the innovative nanotechnology-based tools that may ultimately prove effective at eradicating metastatic diseases.en_US
dc.identifier.citationZhang, Peisen, Meng, Junli, Li, Yingying, et al.. "Nanotechnology-enhanced immunotherapy for metastatic cancer." <i>The Innovation,</i> 2, no. 4 (2021) Elsevier: https://doi.org/10.1016/j.xinn.2021.100174.en_US
dc.identifier.digital1-s2-0-S2666675821000990-mainen_US
dc.identifier.doihttps://doi.org/10.1016/j.xinn.2021.100174en_US
dc.identifier.urihttps://hdl.handle.net/1911/111710en_US
dc.language.isoengen_US
dc.publisherElsevieren_US
dc.rightsThis is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).en_US
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/).en_US
dc.titleNanotechnology-enhanced immunotherapy for metastatic canceren_US
dc.typeJournal articleen_US
dc.type.dcmiTexten_US
dc.type.publicationpublisher versionen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
1-s2-0-S2666675821000990-main.pdf
Size:
7.69 MB
Format:
Adobe Portable Document Format